Please use this identifier to cite or link to this item:
|Title:||Current and emerging surveillance strategies to expand the window of opportunity for curative treatment after surgery in colorectal cancer|
|Authors:||Lin Koo, S.|
circulating tumor cells
|Source:||Lin Koo, S., Wen, J.H., Hillmer, A., Cheah, P.Y., Tan, P., Tan, I.B. (2013-04). Current and emerging surveillance strategies to expand the window of opportunity for curative treatment after surgery in colorectal cancer. Expert Review of Anticancer Therapy 13 (4) : 439-450. ScholarBank@NUS Repository. https://doi.org/10.1586/era.13.14|
|Abstract:||Colorectal cancer is the third most common cancer globally. At diagnosis, more than 70% of patients have nonmetastatic disease. Cure rates for early-stage colorectal cancer have improved with primary screening, improvements in surgical techniques and advances in adjuvant chemotherapy. Despite optimal primary treatment, 30-50% of these patients will still relapse. While death will result from widespread metastatic disease, patients with small volume oligometastatic disease are still considered curable with aggressive multimodality therapy. Hence, early detection of relapsed cancer when it is still amenable to resection expands the window of opportunity for cure. Here, the authors review the modalities currently employed in clinical practice and the evidence supporting intensive surveillance strategies. The authors also discuss ongoing clinical trials examining specific surveillance programs and emerging modalities that may be deployed in the future for early detection of metastatic disease. © 2013 2013 Expert Reviews Ltd.|
|Source Title:||Expert Review of Anticancer Therapy|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 14, 2018
WEB OF SCIENCETM
checked on Jan 16, 2018
checked on Feb 18, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.